Free Account Opening + AMC Free Demat
Loading...

Parabolic Drugs IPO vs Standard Chartered IDR

Comparision between Parabolic Drugs IPO and Standard Chartered IDR.

IPO Details

Parabolic Drugs IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Standard Chartered IDR is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Parabolic Drugs IPO is up to ₹200.00 Cr whereas the issue size of the Standard Chartered IDR is up to ₹2,486.35 Cr. The final issue price of Parabolic Drugs IPO is ₹75.00 per share and of Standard Chartered IDR is ₹104.00 per share.

  Parabolic Drugs IPO Standard Chartered IDR
Face Value ₹10 per share
Issue Price (Lower) ₹75.00 per share ₹100.00 per share
Issue Price (Upper) ₹85.00 per share ₹115.00 per share
Issue Price (Final) ₹75.00 per share ₹104.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 80 shares 200 shares
Fresh Issue Size
Fresh Issue Size (Amount)
OFS Issue Size
OFS Issue Size (Amount)
Issue Size Total 2,66,66,667 shares 24,00,00,000 shares
Issue Size Total (Amount) up to ₹200.00 Cr up to ₹2,486.35 Cr

IPO Timetable

Parabolic Drugs IPO opens on Jun 14, 2010, while Standard Chartered IDR opens on May 25, 2010. The closing date of Parabolic Drugs IPO and Standard Chartered IDR is Jun 17, 2010, and May 28, 2010, respectively.

  Parabolic Drugs IPO Standard Chartered IDR
Anchor Bid Date
Issue Open Jun 14, 2010 May 25, 2010
Issue Close Jun 17, 2010 May 28, 2010
Basis Of Allotment (Tentative)
Initiation of Refunds (Tentative)
Credit of Share (Tentative)
Listing date (Tentative)
Anchor Lockin End date 1
Anchor Lockin End date 2

Financials

Parabolic Drugs IPO P/E ratio is , as compared to Standard Chartered IDR P/E ratio of .

  Parabolic Drugs IPO Standard Chartered IDR
Financial
ParticularsFor the year/period ended (Rs. in Crore)
30-Sept-0931-Mar-0931-Mar-0831-Mar-0731-Mar-0631-Mar-05
Total Income233.43396.94273.94150.5690.1250.90
Profit After Tax (PAT)12.4121.0929.6713.588.223.27
Promoter Shareholding (Pre-Issue) 63.2%
Promoter Shareholding (Post-Issue) 46.5%
P/E Ratio
Market Cap
ROE
ROCE 6.21%%
Debt/Equity
EPS
RoNW 19.96%% 14.3%%

Shares Offered

In the Parabolic Drugs IPO retail investors (RII) are offered 91,58,334 shares while in Standard Chartered IDR retail investors are offered 91,58,334 shares. Qualified institutional buyers (QIB) are offered 1,30,83,333 shares in Parabolic Drugs IPO and 8,40,00,000 shares in Standard Chartered IDR.

  Parabolic Drugs IPO Standard Chartered IDR
Anchor Investor Reserveration
Market Maker Reserveration
QIB 1,30,83,333 shares 8,40,00,000 shares
NII 39,25,000 shares 4,32,00,000 shares
RII 91,58,334 shares 7,20,00,000 shares
Employee 5,00,000 shares 48,00,000 shares
Others
Total 2,66,66,667 shares 20,40,00,000 shares

Bids Received (Subscription)

Parabolic Drugs IPO subscribed 1.04x in total, whereas Standard Chartered IDR subscribed 2.20x.

  Parabolic Drugs IPO Standard Chartered IDR
QIB (times) 1.48x 4.15x
NII (times) 1.20x 1.90x
Big NII (times)
Small NII (times)
RII (times) 0.40x 0.25x
Employee (times) 0.11x 0.20x
Other (times)
Total (times) 1.04x 2.20x

Comments

Add a public comment...